Kodiak Sciences Rises as Investors Focus on Fresh Clinical Visibility After Phase 3 Win

2026-10-09

Investivoq PriceTracker

Kodiak Sciences (KOD) is up 6.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed attention on Kodiak’s retina pipeline as the company heads into AAO 2026, where it is scheduled to give the first scientific presentation of its recently announced Phase 3 DAYBREAK results. Investor sentiment likely remains supported by the late-September data package, which showed both Zenkuda and KSI-501 met primary endpoints in wet AMD and kept the company on track for a planned Zenkuda BLA filing in the fourth quarter of 2026.

Details:

On October 7, Kodiak said it will present clinical data across all three late-stage programs at AAO 2026, with the DAYBREAK results scheduled for presentation on October 9.

On September 28, the company said Zenkuda and tabirafusp-ted each met the primary endpoint in the pivotal DAYBREAK trial in wet age-related macular degeneration.

Kodiak said 54% of Zenkuda-treated patients reached a 24-week dosing interval at year one under strict retreatment criteria, a durability outcome that may be helping sustain enthusiasm around the asset.

The company previously said it ended the second quarter with $125.9 million in cash and expects current resources to support operations into 2027, which may help investors focus on upcoming clinical and regulatory milestones.

Sources:

Kodiak Sciences, SEC, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$KOD Insider Trading Activity

$KOD insiders have traded $KOD stock on the open market 32 times in the past 6 months. Of those trades, 30 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $KOD stock by insiders over the last 6 months:

BROS. ADVISORS LP BAKER has made 30 purchases buying 807,840 shares for an estimated $58,625,707 and 0 sales.
JOHN A. BORGESON (Chief Financial Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $1,023,008.

To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

EARLY ACCESS

Receive KOD Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$KOD Hedge Fund Activity

We have seen 108 institutional investors add shares of $KOD stock to their portfolio, and 78 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,463,832 shares (+11088.8%) to their portfolio in Q2 2026, for an estimated $57,030,894
PRICE T ROWE ASSOCIATES INC /MD/ added 1,209,261 shares (+59.3%) to their portfolio in Q2 2026, for an estimated $47,112,808
BALYASNY ASSET MANAGEMENT L.P. removed 680,101 shares (-93.6%) from their portfolio in Q2 2026, for an estimated $26,496,734
GOLDMAN SACHS GROUP INC added 627,011 shares (+37.1%) to their portfolio in Q2 2026, for an estimated $24,428,348
SILVERARC CAPITAL MANAGEMENT, LLC removed 445,674 shares (-44.9%) from their portfolio in Q2 2026, for an estimated $17,363,459
TWO SIGMA INVESTMENTS, LP added 373,533 shares (+375.5%) to their portfolio in Q2 2026, for an estimated $14,552,845
POINT72 ASSET MANAGEMENT, L.P. removed 362,126 shares (-78.8%) from their portfolio in Q2 2026, for an estimated $14,108,428

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.